Ardelyx reported a total revenue of $73.2 million for the second quarter of 2024, driven by net product sales of IBSRELA and XPHOZAH. The company ended the quarter with approximately $186 million in cash and investments. Net loss for the quarter was $16.5 million, or $(0.07) per share.
IBSRELA generated $35.4 million in net product sales revenue.
XPHOZAH generated $37.1 million in net product sales revenue.
The company had total cash, cash equivalents and short-term investments of $186.0 million as of June 30, 2024.
Net loss for the quarter ended June 30, 2024 was $16.5 million, or $(0.07) per share.
Ardelyx expects full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance